Appendixes



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 95
An Assessment of the NIH Women's Health Initiative Appendixes

OCR for page 95
An Assessment of the NIH Women's Health Initiative This page in the original is blank.

OCR for page 95
An Assessment of the NIH Women's Health Initiative A Clinical Trial Exclusion Criteria (June 28, 1993, WHI Protocol) Exclusion Criteria for All Components Competing Risk: Any medical condition associated with predicted survival of less than three years in the judgment of a Clinic physician (e.g., class IV congestive heart failure, obstructive lung disease requiring long-term ventilation or supplemental oxygen in the past, severe chronic liver disease with jaundice or ascites, kidney failure requiring dialysis, sickle cell anemia) Adherence or Retention Reasons alcoholism other drug dependency mental illness, including severe depression dementia active participant in any other intervention trial where participants are individually randomized to an intervention or control group Additional Exclusion Criteria for All Clinical Trial Components Competing Risk invasive cancer of any type in the past 10 years breast cancer at any time (in situ or invasive) any medical condition associated with predicted survival of less than five years in the judgment of a Clinic physician (e.g., class IV congestive heart failure, obstructive lung disease requiring long-term ventilation or supplemental oxygen in the past, severe chronic liver disease with jaundice or ascites, kidney failure requiring dialysis, sickle cell anemia) SOURCE: Adapted from National Institute of Health's WHI Protocol, June 28, 1993, p.28.

OCR for page 95
An Assessment of the NIH Women's Health Initiative baseline mammogram or clinical breast examination findings suspicious of breast cancer (see MOOP for detailed criteria) * acute myocardial infarction in past six months * stroke or transient ischemic attack (TIA) within the past six months * known chronic active hepatitis or severe cirrhosis Safety reasons severely underweight (BMI < 18 kg/m2 or loss of 15 or more pounds in previous six months) hematocrit < 34% or hemoglobin < 11.5 gm/dl * platelets < 75,000 cells/ml severe hypertension (systolic BP > 200 mmHg or diastolic BP > 105 mmHg)* current use of oral daily corticosteroids for more than six months Adherence or retention reasons BMI > 40 kg/m2 unwilling to participate in baseline or yearly examination components such as yearly mammograms, clinical breast exams, phlebotomy, electrocardiograms, questionnaires and forms; or unable to complete baseline study requirements Additional Exclusion Criteria for Hormone Replacement Component Safety reasons endometrial cancer of any stage at any time endometrial hyperplasia at baseline biopsy or endometrial thickness > 5mm via ultrasonography (no recycling) malignant melanoma of any stage at any time non-traumatic thromboembolic event or thromboembolic event associated with estrogen or oral contraceptive use previous osteoporosis-related fracture being treated with hormone replacement therapy history of bleeding disorder serious enough to require transfusion known history of hypertriglyceridemia, or lipemic serum leading to diagnosis of hypertriglyceridemia on baseline blood draw deep vein thrombosis or pulmonary embolism in past six months* currently on anticoagulants * currently on tamoxifen * Implies that a woman who is temporarily excluded may be reevaluated for eligibility as appropriate to the excluding condition. If more than six months have elapsed since the woman's first screening visit, however, all baseline and screening activities must be repeated.

OCR for page 95
An Assessment of the NIH Women's Health Initiative Adherence or retention reasons severe menopausal symptoms that would make placebo therapy intolerable to the participant inadequate adherence with placebo run-in (less than 80% of pills taken) unable or unwilling to discontinue use of hormone replacement therapy (women must discontinue current replacement hormone therapy for at least three months in order to be eligible for the HRT)* unwilling to have baseline or yearly endometrial aspirations* Additional Exclusion Criteria for Dietary Modification Component Adherence or retention reasons special dietary requirements incompatible with the intervention diet (such as celiac sprue, other malabsorption syndromes, use of MAO inhibitors). Women will be eligible if they are following a diabetic diet or a low salt diet colorectal cancer at any time unable to complete Four-Day Food Record adequately percent of calories from fat estimated to be 34 or less number of main meals prepared out of home ≥ 10 per week type I (insulin-requiring, ketosis-prone) diabetes mellitus gastrointestinal conditions that contraindicate a high fiber diet Additional Exclusion Criteria for Calcium/Vitamin D Component Safety reasons History of renal calculi Adherence or retention reasons unable or unwilling to discontinue use of calcium or vitamin D supplements inadequate adherence with HRT and/or DM trial components during the first year of followup (see Manual of Operations and Procedures for detailed criteria)

OCR for page 95
An Assessment of the NIH Women's Health Initiative This page in the original is blank.